Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumour necrosis factor-α

European Journal of Surgical Oncology

Volumn 32, Issue 4, 2006, Pages 371-380

  Grunhagen D J ^a   de Wilt, J H W ^a   van Geel, A N ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated limb perfusion; Melanoma; Review; TNF

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CANCER VACCINE; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; GAMMA INTERFERON; INDOMETACIN; INTERFERON; MELPHALAN; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; BLISTER; CANCER CONTROL; CARBON DIOXIDE LASER; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FEVER; DRUG POTENTIATION; EPIDERMOLYSIS; ERYTHEMA; FUNCTIONAL DISEASE; HUMAN; HYPERTHERMIA; HYPOTENSION; LIMB PERFUSION; LIMB SALVAGE; LYMPH NODE METASTASIS; MEDLINE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN EDEMA; SURVIVAL RATE; SYSTEMIC DISEASE; TREATMENT OUTCOME; VASCULAR DISEASE; LIMB; METHODOLOGY; REGIONAL PERFUSION; SKIN TUMOR;

CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746052513     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.01.015     Document Type: Review

References (108)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. CA Cancer J Clin 55 (2005) 10-30
3. de Vries E., van de Poll-Franse L.V., Louwman W.J., de Gruijl F.R., and Coebergh J.W. Predictions of skin cancer incidence in The Netherlands up to 2015. Br J Dermatol 152 (2005) 481-488
4. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
5. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
6. Cox K.R. Survival after amputation for recurrent melanoma. Surg Gynecol Obstet 139 (1974) 720-722
7. Hill S., and Thomas J.M. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 83 (1996) 509-512
8. Strobbe L.J., Nieweg O.E., and Kroon B.B. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 23 (1997) 435-438
9. Byrne C.M., Thompson J.F., Johnston H., Hersey P., Quinn M.J., Michael Hughes T., et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15 (2005) 45-51
10. Rols M.P., Bachaud J.M., Giraud P., Chevreau C., Roche H., and Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 10 (2000) 468-474
11. Heller R., Jaroszeski M.J., Reintgen D.S., Puleo C.A., DeConti R.C., Gilbert R.A., et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83 (1998) 148-157
12. Hsueh E.C., Nathanson L., Foshag L.J., Essner R., Nizze J.A., Stern S.L., et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85 (1999) 2160-2169
13. Rochlitz C., Dreno B., Jantscheff P., Cavalli F., Squiban P., Acres B., et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 9 (2002) 289-295
14. Marchand M., Punt C.J., Aamdal S., Escudier B., Kruit W.H., Keilholz U., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39 (2003) 70-77
15. Fenig E., Eidelevich E., Njuguna E., Katz A., Gutman H., Sulkes A., et al. Role of radiation therapy in the management of cutaneous malignant melanoma. Am J Clin Oncol 22 (1999) 184-186
16. Seegenschmiedt M.H., Keilholz L., Altendorf-Hofmann A., Urban A., Schell H., Hohenberger W., et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20 year experience. Int J Radiat Oncol Biol Phys 44 (1999) 607-618
17. Overgaard J., Gonzalez Gonzalez D., Hulshof M.C., Arcangeli G., Dahl O., Mella O., et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European society for hyperthermic oncology. Lancet 345 (1995) 540-543
18. Eggermont A.M., and Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 40 (2004) 1825-1836
19. Calabro A., Singletary S.E., Carrasco C.H., and Legha S.S. Intraarterial infusion chemotherapy in regionally advanced malignant melanoma. J Surg Oncol 43 (1990) 239-244
20. Karakousis C.P., Kontzoglou K., and Driscoll D.L. Tourniquet infusion chemotherapy for extremity in-transit lesions in malignant melanoma. Ann Surg Oncol 4 (1997) 506-510
21. Creech Jr. O., Krementz E.T., Ryan R.F., and Winblad J.N. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148 (1958) 616-632
22. Benckhuijsen C., Kroon B.B., van Geel A.N., and Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14 (1988) 157-163
23. Thompson J.F., and Gianoutsos M.P. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16 (1992) 227-233
24. Klaase J.M., Kroon B.B., van Geel A.N., Eggermont A.M., and Franklin H.R. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 80 (1993) 1124-1126
25. World Health Organisation. WHO handbook for reporting results of cancer treatment (1979), World Health Organisation, Geneva
26. Wieberdink J., Benckhuysen C., Braat R.P., van Slooten E.A., and Olthuis G.A. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18 (1982) 905-910
27. Omlor G. Optimization of isolated hyperthermic limb perfusion. World J Surg 17 (1993) 134
28. Cavaliere R., Ciocatto E.C., Giovanella B.C., Heidelberger C., Johnson R.O., Margottini M., et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20 (1967) 1351-1381
29. Clark J., Grabs A.J., Parsons P.G., Smithers B.M., Addison R.S., and Roberts M.S. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 4 (1994) 365-370
30. Klaase J.M., Kroon B.B., van Geel A.N., van Wijk J., Franklin H.R., Eggermont A.M., et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 178 (1994) 564-572
31. Di Filippo F., Anza M., Rossi C.R., Cavaliere F., Botti C., Lise M., et al. The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 14 (1998) 215-223
32. Kroon B.B., Klaase J.M., van Geel A.N., and Eggermont A.M. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 4 (1992) 223-226
33. Vaglini M., Andreola S., Attili A., Belli F., Marolda R., Nava M., et al. Hyperthermic antiblastic perfusion in the treatment of cancer of the extremities. Tumori 71 (1985) 355-359
34. Storm F.K., and Morton D.L. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 150 (1985) 32-35
35. Bryant P.J., Balderson G.A., Mead P., and Egerton W.S. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 19 (1995) 363-368
36. Thompson J.F., Hunt J.A., Shannon K.F., and Kam P.C. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 132 (1997) 903-907
37. Lejeune F.J., Deloof T., Ewalenko P., Fruhling J., Jabri M., Mathieu M., et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 86 (1983) 268-276
38. Minor D.R., Allen R.E., Alberts D., Peng Y.M., Tardelli G., and Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 55 (1985) 2638-2644
39. Skene A.I., Bulman A.S., Williams T.R., Thomas J.M., and Westbury G. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 77 (1990) 765-767
40. Kettelhack C., Kraus T., Hupp T., Manner M., and Schlag P. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 16 (1990) 370-375
41. Lejeune F.J. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 31A (1995) 1009-1016
42. Lingam M.K., Byrne D.S., Aitchison T., MacKie R.M., and McKay A.J. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 32A (1996) 1668-1673
43. McBride C.M., Sugarbaker E.V., and Hickey R.C. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 182 (1975) 316-324
44. Koops H.S., Vaglini M., Suciu S., Kroon B.B., Thompson J.F., Gohl J., et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European organization for research and treatment of cancer malignant melanoma cooperative group protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16 (1998) 2906-2912
45. Hafstrom L., Rudenstam C.M., Blomquist E., Ingvar C., Jonsson P.E., Lagerlof B., et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish melanoma study group. J Clin Oncol 9 (1991) 2091-2094
46. Vrouenraets B.C., Nieweg O.E., and Kroon B.B. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83 (1996) 1319-1328
47. Thompson J.F., Waugh R.C., Saw R.P., and Kam P.C. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 7 (1994) 188-192
48. Thompson J.F., Kam P.C., Waugh R.C., and Harman C.R. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14 (1998) 238-247
49. Lindner P., Doubrovsky A., Kam P.C., and Thompson J.F. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 9 (2002) 127-136
50. Thompson J.F., and Kam P.C. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 88 (2004) 1-3
51. Lindner P., Thompson J.F., De Wilt J.H., Colman M., and Kam P.C. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 30 (2004) 433-439
52. Klaase J.M., Kroon B.B., van Geel A.N., Eggermont A.M., Franklin H.R., and van Dongen J.A. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 71 (1993) 2990-2994
53. Noorda E.M., Vrouenraets B.C., Nieweg O.E., Klaase J.M., van der Zee J., and Kroon B.B. Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb. Melanoma Res 13 (2003) 395-399
54. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72 (1975) 3666-3670
55. Sugarman B.J., Aggarwal B.B., Hass P.E., Figari I.S., Palladino Jr. M.A., and Shepard H.M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230 (1985) 943-945
56. Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Neda H., Yamauchi N., et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48 (1988) 2179-2183
57. Feldman E.R., Creagan E.T., Schaid D.J., and Ahmann D.L. Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. Am J Clin Oncol 15 (1992) 256-259
58. Feinberg B., Kurzrock R., Talpaz M., Blick M., Saks S., and Gutterman J.U. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 6 (1988) 1328-1334
59. Asher A., Mule J.J., Reichert C.M., Shiloni E., and Rosenberg S.A. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138 (1987) 963-974
60. Watanabe N., Niitsu Y., Umeno H., Sone H., Neda H., Yamauchi N., et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 48 (1988) 650-653
61. Regenass U., Muller M., Curschellas E., and Matter A. Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 39 (1987) 266-273
62. Lienard D., Ewalenko P., Delmotte J.J., Renard N., and Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10 (1992) 52-60
63. Manusama E.R., Nooijen P.T., Stavast J., Durante N.M., Marquet R.L., and Eggermont A.M. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 83 (1996) 551-555
64. Bauer T.W., Gutierrez M., Dudrick D.J., Li J., Blair I.A., Menon C., et al. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan. Surgery 133 (2003) 420-428
65. Manusama E.R., Stavast J., Durante N.M., Marquet R.L., and Eggermont A.M. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 22 (1996) 152-157
66. de Wilt J.H., ten Hagen T.L., de Boeck G., van Tiel S.T., de Bruijn E.A., and Eggermont A.M. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82 (2000) 1000-1003
67. van der Veen A.H., de Wilt J.H., Eggermont A.M., van Tiel S.T., Seynhaeve A.L., and ten Hagen T.L. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82 (2000) 973-980
68. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., and Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4 (1998) 408-414
69. Nooijen P.T., Eggermont A.M., Schalkwijk L., Henzen-Logmans S., de Waal R.M., and Ruiter D.J. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res 58 (1998) 4880-4887
70. Kristensen C.A., Nozue M., Boucher Y., and Jain R.K. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 74 (1996) 533-536
71. de Wilt J.H., Manusama E.R., van Tiel S.T., van Ijken M.G., ten Hagen T.L., and Eggermont A.M. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80 (1999) 161-166
72. Brouckaert P.G., Leroux-Roels G.G., Guisez Y., Tavernier J., and Fiers W. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 38 (1986) 763-769
73. de Kossodo S., Moore R., Gschmeissner S., East N., Upton C., and Balkwill F.R. Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br J Cancer 72 (1995) 1165-1172
74. Manusama E.R., De Wilt J.H., Ten Hagen T.L., Marquet R.L., and Eggermont A.M. Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep 6 (1999) 173-177
75. Lejeune F.J., Lienard D., Leyvraz S., and Mirimanoff R.O. Regional therapy of melanoma. Eur J Cancer 29A (1993) 606-612
76. Vaglini M., Belli F., Ammatuna M., Inglese M.G., Manzi R., Prada A., et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 73 (1994) 483-492
77. Eggermont A.M., Lienard D., and Schraffordt Koops H. High dose tumor necrosis factor-alpha in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat 7 (1995) 32-36
78. Fraker D.L., Alexander H.R., Andrich M., and Rosenberg S.A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14 (1996) 479-489
79. Lienard D., Eggermont A.M., Koops H.S., Kroon B., Towse G., Hiemstra S., et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9 (1999) 491-502
80. Rossi C.R., Foletto M., Mocellin S., Pilati P., and Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 11 (2004) 173-177
81. Noorda E.M., Vrouenraets B.C., Nieweg O.E., van Geel B.N., Eggermont A.M., and Kroon B.B. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 139 (2004) 1237-1242
82. Grünhagen D.J., Brunstein F., Graveland W.J., van Geel A.N., de Wilt J.H., and Eggermont A.M. One hundred consecutive isolated limb perfusions with TNF-alpha and Melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240 (2004) 939-948
83. Lejeune F., Lienard D., Eggermont A., Schraffordt Koops H., Rosenkaimer F., Gerain J., et al. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 56 (1994) 52-61
84. Fraker D.L., Alexander H.R., Ross M., Bartlett D.L., Tyler D., Libutti L.S., et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 9 (2002) S8
85. Klaase J.M., Kroon B.B., Benckhuijsen C., van Geel A.N., Albus-Lutter C.E., and Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 64 (1989) 616-621
86. Eggermont A.M., Schraffordt Koops H., Lienard D., Kroon B.B., van Geel A.N., Hoekstra H.J., et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14 (1996) 2653-2665
87. Eggermont A.M., Schraffordt Koops H., Klausner J.M., Kroon B.B., Schlag P.M., Lienard D., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224 (1996) 756-764 [discussion 764-755]
88. Hill S., Fawcett W.J., Sheldon J., Soni N., Williams T., and Thomas J.M. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80 (1993) 995-997
89. Bonvalot S., Laplanche A., Lejeune F., Stoeckle E., Le Pechoux C., Vanel D., et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?. Ann Oncol 16 (2005) 1061-1068
90. Grünhagen D.J., de Wilt J.H., van Geel A.N., Graveland W.J., Verhoef C., and Eggermont A.M. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 9 (2005) 1011-1019
91. Klaase J.M., Kroon B.B., van Geel A.N., Eggermont A.M., Franklin H.R., and Hart A.A. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 115 (1994) 39-45
92. Feldman A.L., Alexander Jr. H.R., Bartlett D.L., Fraker D.L., and Libutti S.K. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 6 (1999) 562-567
93. Klop W.M., Vrouenraets B.C., van Geel B.N., Eggermont A.M., Klaase J.M., Nieweg O.E., et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 182 (1996) 467-472
94. Bartlett D.L., Ma G., Alexander H.R., Libutti S.K., and Fraker D.L. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 80 (1997) 2084-2090
95. Grunhagen D.J., van Etten B., Brunstein F., Graveland W.J., van Geel A.N., de Wilt J.H., et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 12 (2005) 609-615
96. Takkenberg R.B., Vrouenraets B.C., van Geel A.N., Nieweg O.E., Noorda E.M., Eggermont A.M., et al. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 91 (2005) 107-111
97. Grünhagen D.J., de Wilt J.H., Graveland W.J., van Geel A.N., and Eggermont A.M. Palliative value of TNF-based isolated limb perfusion in metastatic sarcoma and melanoma patients. Cancer 106 (2006) 156-162
98. Lienard D., Lejeune F.J., and Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16 (1992) 234-240
99. Klaase J.M., Kroon B.B., van Geel B.N., Eggermont A.M., Franklin H.R., and Hart G.A. Patient-and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 167 (1994) 618-620
100. Thompson J.F., Eksborg S., Kam P.C., Ingvar C., Yau D.F., Lai D.T., et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 6 (1996) 267-271
101. Vrouenraets B.C., Eggermont A.M., Hart A.A., Klaase J.M., van Geel A.N., Nieweg O.E., et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 27 (2001) 390-395
102. Vrouenraets B.C., Klaase J.M., Kroon B.B., van Geel B.N., Eggermont A.M., and Franklin H.R. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 130 (1995) 43-47
103. Stam T.C., Swaak A.J., de Vries M.R., ten Hagen T.L., and Eggermont A.M. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 7 (2000) 268-275
104. Swaak A.J., Lienard D., Schraffordt Koops H., Lejeune F.J., and Eggermont A.M. Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 23 (1993) 812-818
105. Thom A.K., Alexander H.R., Andrich M.P., Barker W.C., Rosenberg S.A., and Fraker D.L. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 13 (1995) 264-273
106. Noorda E.M., Vrouenraets B.C., Nieweg O.E., van Geel A.N., Eggermont A.M., and Kroon B.B. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 9 (2002) 968-974
107. van Etten B., van Geel A.N., de Wilt J.H., and Eggermont A.M. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 10 (2003) 32-37
108. Eggermont A.M., de Wilt J.H., and ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4 (2003) 429-437